Neurocrine Biosciences, Inc.

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company whose drug development pipeline necessitates animal testing as part of the regulatory approval process. The company is listed by Cruelty Free Investors for exploiting animals through this testing. Its core business of developing treatments for neurological, endocrine, and psychiatric disorders relies on preclinical animal studies to demonstrate safety and efficacy before human trials, a standard requirement for FDA approval.

While some industry efforts aim to reduce animal testing, Neurocrine Biosciences’ fundamental business model remains dependent on these practices. The company’s New Drug Applications (NDAs) must include results from animal studies, as noted in its regulatory filings. There is no public evidence that the company has committed to adopting alternative testing methods at a scale that would materially reduce its reliance on animal models.